White paper on microbial anti-cancer therapy and prevention

Neil S. Forbes, Robert S. Coffin, Liang Deng, Laura Evgin, Steve Fiering, Matthew Giacalone, Claudia Gravekamp, James L. Gulley, Hal Gunn, Robert M. Hoffman, Balveen Kaur, Ke Liu, Herbert Kim Lyerly, Ariel E. Marciscano, Eddie Moradian, Sheryl Ruppel, Daniel A. Saltzman, Peter J. Tattersall, Steve Thorne, Richard Geoffrey Vile & 3 others Halle Huihong Zhang, Shibin Zhou, Grant McFadden

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In this White Paper, we discuss the current state of microbial cancer therapy. This paper resulted from a meeting ('Microbial Based Cancer Therapy') at the US National Cancer Institute in the summer of 2017. Here, we define 'Microbial Therapy' to include both oncolytic viral therapy and bacterial anticancer therapy. Both of these fields exploit tumor-specific infectious microbes to treat cancer, have similar mechanisms of action, and are facing similar challenges to commercialization. We designed this paper to nucleate this growing field of microbial therapeutics and increase interactions between researchers in it and related fields. The authors of this paper include many primary researchers in this field. In this paper, we discuss the potential, status and opportunities for microbial therapy as well as strategies attempted to date and important questions that need to be addressed. The main areas that we think will have the greatest impact are immune stimulation, control of efficacy, control of delivery, and safety. There is much excitement about the potential of this field to treat currently intractable cancer. Much of the potential exists because these therapies utilize unique mechanisms of action, difficult to achieve with other biological or small molecule drugs. By better understanding and controlling these mechanisms, we will create new therapies that will become integral components of cancer care.

Original languageEnglish (US)
Article number78
JournalJournal for ImmunoTherapy of Cancer
Volume6
Issue number1
DOIs
StatePublished - Aug 6 2018

Fingerprint

Neoplasms
Therapeutics
Research Personnel
National Cancer Institute (U.S.)
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Forbes, N. S., Coffin, R. S., Deng, L., Evgin, L., Fiering, S., Giacalone, M., ... McFadden, G. (2018). White paper on microbial anti-cancer therapy and prevention. Journal for ImmunoTherapy of Cancer, 6(1), [78]. https://doi.org/10.1186/s40425-018-0381-3

White paper on microbial anti-cancer therapy and prevention. / Forbes, Neil S.; Coffin, Robert S.; Deng, Liang; Evgin, Laura; Fiering, Steve; Giacalone, Matthew; Gravekamp, Claudia; Gulley, James L.; Gunn, Hal; Hoffman, Robert M.; Kaur, Balveen; Liu, Ke; Lyerly, Herbert Kim; Marciscano, Ariel E.; Moradian, Eddie; Ruppel, Sheryl; Saltzman, Daniel A.; Tattersall, Peter J.; Thorne, Steve; Vile, Richard Geoffrey; Zhang, Halle Huihong; Zhou, Shibin; McFadden, Grant.

In: Journal for ImmunoTherapy of Cancer, Vol. 6, No. 1, 78, 06.08.2018.

Research output: Contribution to journalArticle

Forbes, NS, Coffin, RS, Deng, L, Evgin, L, Fiering, S, Giacalone, M, Gravekamp, C, Gulley, JL, Gunn, H, Hoffman, RM, Kaur, B, Liu, K, Lyerly, HK, Marciscano, AE, Moradian, E, Ruppel, S, Saltzman, DA, Tattersall, PJ, Thorne, S, Vile, RG, Zhang, HH, Zhou, S & McFadden, G 2018, 'White paper on microbial anti-cancer therapy and prevention', Journal for ImmunoTherapy of Cancer, vol. 6, no. 1, 78. https://doi.org/10.1186/s40425-018-0381-3
Forbes NS, Coffin RS, Deng L, Evgin L, Fiering S, Giacalone M et al. White paper on microbial anti-cancer therapy and prevention. Journal for ImmunoTherapy of Cancer. 2018 Aug 6;6(1). 78. https://doi.org/10.1186/s40425-018-0381-3
Forbes, Neil S. ; Coffin, Robert S. ; Deng, Liang ; Evgin, Laura ; Fiering, Steve ; Giacalone, Matthew ; Gravekamp, Claudia ; Gulley, James L. ; Gunn, Hal ; Hoffman, Robert M. ; Kaur, Balveen ; Liu, Ke ; Lyerly, Herbert Kim ; Marciscano, Ariel E. ; Moradian, Eddie ; Ruppel, Sheryl ; Saltzman, Daniel A. ; Tattersall, Peter J. ; Thorne, Steve ; Vile, Richard Geoffrey ; Zhang, Halle Huihong ; Zhou, Shibin ; McFadden, Grant. / White paper on microbial anti-cancer therapy and prevention. In: Journal for ImmunoTherapy of Cancer. 2018 ; Vol. 6, No. 1.
@article{57d306ffcc0842bbbef5cdd18a02b5c2,
title = "White paper on microbial anti-cancer therapy and prevention",
abstract = "In this White Paper, we discuss the current state of microbial cancer therapy. This paper resulted from a meeting ('Microbial Based Cancer Therapy') at the US National Cancer Institute in the summer of 2017. Here, we define 'Microbial Therapy' to include both oncolytic viral therapy and bacterial anticancer therapy. Both of these fields exploit tumor-specific infectious microbes to treat cancer, have similar mechanisms of action, and are facing similar challenges to commercialization. We designed this paper to nucleate this growing field of microbial therapeutics and increase interactions between researchers in it and related fields. The authors of this paper include many primary researchers in this field. In this paper, we discuss the potential, status and opportunities for microbial therapy as well as strategies attempted to date and important questions that need to be addressed. The main areas that we think will have the greatest impact are immune stimulation, control of efficacy, control of delivery, and safety. There is much excitement about the potential of this field to treat currently intractable cancer. Much of the potential exists because these therapies utilize unique mechanisms of action, difficult to achieve with other biological or small molecule drugs. By better understanding and controlling these mechanisms, we will create new therapies that will become integral components of cancer care.",
author = "Forbes, {Neil S.} and Coffin, {Robert S.} and Liang Deng and Laura Evgin and Steve Fiering and Matthew Giacalone and Claudia Gravekamp and Gulley, {James L.} and Hal Gunn and Hoffman, {Robert M.} and Balveen Kaur and Ke Liu and Lyerly, {Herbert Kim} and Marciscano, {Ariel E.} and Eddie Moradian and Sheryl Ruppel and Saltzman, {Daniel A.} and Tattersall, {Peter J.} and Steve Thorne and Vile, {Richard Geoffrey} and Zhang, {Halle Huihong} and Shibin Zhou and Grant McFadden",
year = "2018",
month = "8",
day = "6",
doi = "10.1186/s40425-018-0381-3",
language = "English (US)",
volume = "6",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - White paper on microbial anti-cancer therapy and prevention

AU - Forbes, Neil S.

AU - Coffin, Robert S.

AU - Deng, Liang

AU - Evgin, Laura

AU - Fiering, Steve

AU - Giacalone, Matthew

AU - Gravekamp, Claudia

AU - Gulley, James L.

AU - Gunn, Hal

AU - Hoffman, Robert M.

AU - Kaur, Balveen

AU - Liu, Ke

AU - Lyerly, Herbert Kim

AU - Marciscano, Ariel E.

AU - Moradian, Eddie

AU - Ruppel, Sheryl

AU - Saltzman, Daniel A.

AU - Tattersall, Peter J.

AU - Thorne, Steve

AU - Vile, Richard Geoffrey

AU - Zhang, Halle Huihong

AU - Zhou, Shibin

AU - McFadden, Grant

PY - 2018/8/6

Y1 - 2018/8/6

N2 - In this White Paper, we discuss the current state of microbial cancer therapy. This paper resulted from a meeting ('Microbial Based Cancer Therapy') at the US National Cancer Institute in the summer of 2017. Here, we define 'Microbial Therapy' to include both oncolytic viral therapy and bacterial anticancer therapy. Both of these fields exploit tumor-specific infectious microbes to treat cancer, have similar mechanisms of action, and are facing similar challenges to commercialization. We designed this paper to nucleate this growing field of microbial therapeutics and increase interactions between researchers in it and related fields. The authors of this paper include many primary researchers in this field. In this paper, we discuss the potential, status and opportunities for microbial therapy as well as strategies attempted to date and important questions that need to be addressed. The main areas that we think will have the greatest impact are immune stimulation, control of efficacy, control of delivery, and safety. There is much excitement about the potential of this field to treat currently intractable cancer. Much of the potential exists because these therapies utilize unique mechanisms of action, difficult to achieve with other biological or small molecule drugs. By better understanding and controlling these mechanisms, we will create new therapies that will become integral components of cancer care.

AB - In this White Paper, we discuss the current state of microbial cancer therapy. This paper resulted from a meeting ('Microbial Based Cancer Therapy') at the US National Cancer Institute in the summer of 2017. Here, we define 'Microbial Therapy' to include both oncolytic viral therapy and bacterial anticancer therapy. Both of these fields exploit tumor-specific infectious microbes to treat cancer, have similar mechanisms of action, and are facing similar challenges to commercialization. We designed this paper to nucleate this growing field of microbial therapeutics and increase interactions between researchers in it and related fields. The authors of this paper include many primary researchers in this field. In this paper, we discuss the potential, status and opportunities for microbial therapy as well as strategies attempted to date and important questions that need to be addressed. The main areas that we think will have the greatest impact are immune stimulation, control of efficacy, control of delivery, and safety. There is much excitement about the potential of this field to treat currently intractable cancer. Much of the potential exists because these therapies utilize unique mechanisms of action, difficult to achieve with other biological or small molecule drugs. By better understanding and controlling these mechanisms, we will create new therapies that will become integral components of cancer care.

UR - http://www.scopus.com/inward/record.url?scp=85051295512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051295512&partnerID=8YFLogxK

U2 - 10.1186/s40425-018-0381-3

DO - 10.1186/s40425-018-0381-3

M3 - Article

VL - 6

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 78

ER -